Blinatumomab Market Analysis by Indication (Acute Lymphoblastic Leukemia (ALL), Age Group (Adults, Pediatric Patients), by Treatment Line (First-Line Therapy, Relapsed/Refractory Therapy),by Distribution Channel (Hospital Pharmacies, Specialty Clinics) and by Region: Global Forecast, 2024 - 2034
- PUBLISHED ON
- 2024-05-07
- NO OF PAGES
- 191
- CATEGORY
- Healthcare & Life Sciences
Market Overview
The Blinatumomab market is predicted to develop at a compound annual growth rate (CAGR) of xx% from 2024 to 2034, when it is projected to reach USD xx Million, based on an average growth pattern. The market is estimated to reach a value of USD xx Million in 2024.
SOURCE: We Market Research
A
biopharmaceutical drug called Blinatumomab, sometimes referred to as blina, is
marketed under the brand name Blincyto and is used as a second-line treatment
for acute lymphoblastic leukemia that lacks the Philadelphia chromosome and has
relapsed or become resistant to treatment. It is a member of the class of
artificial monoclonal antibodies known as bi-specific T-cell engagers (BiTEs),
which function specifically to trigger the immune system's attack on tumor
cells. Blinatumomab selectively targets the B cell surface antigen known as
CD19.The US Food and Drug Administration authorized it in December 2014 under
the rapid approval program; at the time of approval, marketing permission was
contingent upon the results of ongoing clinical trials.A drip is used to
provide Blinatumomab intravenously.
The ability of Blinatumomab to treat unmet medical needs, particularly in relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), is one of the key factors driving the global market for this medication. Blinatumomab is a novel immunotherapy that utilizes bispecific T-cell engager (BiTE) technology. It has been shown to have good clinical efficacy and safety, as evidenced by regulatory approvals and positive real-world results. Personalized treatment trends, growing healthcare infrastructure, and an increase in ALL incidence all contribute to the market's growth. The advancement of leukemia treatment is attributed to Blinatumomab, which is also important in improving outcomes for patients with limited therapeutic alternatives. These developments are supported by strategic market expansion activities and patient-centric methods.
Market Scope
|
Report Attributes |
Description |
|
Market Size in 2024 |
USD xx Million |
|
Market Forecast in 2034 |
USD xx Million |
|
CAGR % 2024-2034 |
xx% |
|
Base Year |
2023 |
|
Historic Data |
2016-2022 |
|
Forecast Period |
2024-2034 |
|
Report USP
|
Production, Consumption, company share, company
heatmap, company production capacity, growth factors and more |
|
Segments Covered |
by Indication, by Treatment Line, by Distribution Channel and By
Region |
|
Regional Scope |
North America, Europe, APAC, South America and
Middle East and Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic
Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia;
Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa;
Nigeria |
Blinatumomab Industry: Dynamics & Restrains
Market opportunity:
Market Research: Blinatumomab Dashboard
Our marketing platform offers a comprehensive dashboard that provides clients with valuable insights into market trends over the years. Included below is a sample image of our dashboard, and specific PDF logins will be furnished to grant access to this insightful tool.
Blinatumomab Segmentation
Market- By Indication Analysis
By Indication, the Blinatumomab Market is Categories into Acute Lymphoblastic Leukemia (ALL). The Acute Lymphoblastic Leukemia (ALL) segment accounts for the largest share in 2024.
The need for efficient therapies for
relapsed or resistant cases, as well as rising incidence rates, especially in
adults, are the main factors driving the acute lymphoblastic leukemia (ALL)
market for Blinatumomab globally. Targeted medicines like Blinatumomab are
being developed and adopted as a result of advances in personalized medicine
and the biology of leukemia.
The
following segments are part of an in-depth analysis of the global Blinatumomab
market:
|
Market Segments |
|
|
By Age
Group |
·
Adults ·
Pediatric Patients |
|
By Treatment
Line |
·
First-Line Therapy ·
Relapsed/Refractory Therapy |
|
By Distribution
Channel |
·
Hospital Pharmacies ·
Specialty Clinics |
Blinatumomab Industry: Regional Analysis
North America Market Forecast
North America dominate the Blinatumomab Market with the highest revenue generating market with share of more than 47%. The North American market for Blinatumomab is driven by high spending and a sophisticated healthcare infrastructure. Growth is aided by a large pharmaceutical presence and attractive reimbursement. Increasing ALL prevalence drives demand in spite of financial and regulatory obstacles.
Europe Market Statistics
Europe's Blinatumomab market benefits from Demand for Blinatumomab is increased by government programs and rising cancer awareness. Investments in research increase with ALL instances. Regulations and price caps present obstacles to market growth.
Asia Pacific Market Forecasts
Asia Pacific is
expected to be the fastest-growing regional segment of the Blinatumomab market
during the forecast period. In the Asia Pacific region, rising healthcare costs
and a huge population are driving the Blinatumomab market. Demand is driven by
the rising prevalence of ALL in significant markets like China and India. The
intricacy of the laws and the disparities in healthcare quality are the
barriers.
Key Market Players
The Blinatumomab Market is dominated by a few large
companies, such as
· Amgen
· Other
1.
Global
Blinatumomab Market Introduction and Market Overview
1.1. Objectives of the Study
1.2. Global Blinatumomab Market Scope
and Market Estimation
1.2.1. Global Blinatumomab Overall
Market Size, Revenue (US$ Mn), Market CAGR (%), Market forecast (2023 - 2034)
1.2.2. Global Blinatumomab Market
Revenue Share (%) and Growth Rate (Y-o-Y) from 2019 - 2034
1.3. Market Segmentation
1.3.1. Indication of Global Blinatumomab
Market
1.3.2. Age Group of Global Blinatumomab
Market
1.3.3. Treatment Line of Global Blinatumomab
Market
1.3.4. Distribution Channel of Global Blinatumomab
Market
1.3.5. Region of Global Blinatumomab
Market
2.
Executive Summary
2.1. Global Blinatumomab Market Industry Trends under COVID-19 Outbreak
2.1.1. Global COVID-19 Status Overview
2.1.2. Influence of COVID-19 Outbreak
on Global Blinatumomab Market
Industry Development
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Limitations
2.2.3. Opportunities
2.2.4. Impact Analysis of Drivers and
Restraints
2.3. Pricing Trends Analysis &
Average Selling Prices (ASPs)
2.4. Key Mergers & Acquisitions,
Expansions, JVs, Funding / VCs, etc.
2.5. Porter’s Five Forces Analysis
2.5.1. Bargaining Power of Suppliers
2.5.2. Bargaining Power of Buyers
2.5.3. Threat of Substitutes
2.5.4. Threat of New Entrants
2.5.5. Competitive Rivalry
2.6. Value Chain / Ecosystem Analysis
2.7. Russia-Ukraine War Impacts
Analysis
2.8. Economic Downturn Analysis
2.9. Market Investment Opportunity
Analysis (Top Investment Pockets), By Segments & By Region
3.
Global Blinatumomab Market Estimates & Historical Trend Analysis (2019 -
2023)
4.
Global Blinatumomab Market Estimates & Forecast Trend Analysis, by
INDICATION
4.1. Global Blinatumomab Market
Revenue (US$ Mn) Estimates and Forecasts, by INDICATION, 2019 to 2034
4.1.1. Acute Lymphoblastic Leukemia
(ALL)
5.
Global Blinatumomab Market Estimates & Forecast Trend Analysis, by
Age Group
5.1. Global Blinatumomab Market
Revenue (US$ Mn) Estimates and Forecasts, by Age Group, 2019 to 2034
5.1.1. Adults
5.1.2. Pediatric Patients
6.
Global Blinatumomab Market Estimates & Forecast Trend Analysis, by
Treatment Line
6.1. Global Blinatumomab Market
Revenue (US$ Mn) Estimates and Forecasts, by Treatment Line,
2019 to 2034
6.1.1. First-Line Therapy
6.1.2. Relapsed/Refractory Therapy
7.
Global Blinatumomab Market Estimates & Forecast Trend Analysis, by
DISTRIBUTION CHANNEL
7.1. Global Blinatumomab Market
Revenue (US$ Mn) Estimates and Forecasts, by Treatment Line,
2019 to 2034
7.1.1. Hospital Pharmacies
7.1.2. Specialty Clinics
8.
Global Blinatumomab Market Estimates & Forecast Trend Analysis,
by Region
8.1. Global Blinatumomab Market
Revenue (US$ Mn) Estimates and Forecasts, by Region, 2019 to 2034
8.1.1. North America
8.1.2. Europe
8.1.3. Asia Pacific
8.1.4. Middle East & Africa
8.1.5. South America
9.
North
America Blinatumomab Market: Estimates & Forecast Trend Analysis
9.1.
North
America Blinatumomab Market Assessments & Key Findings
9.1.1. North America Blinatumomab
Market Introduction
9.1.2. North America Blinatumomab
Market Size Estimates and Forecast (US$ Million) (2019 – 2034)
9.1.2.1. By INDICATION
9.1.2.2. By Age Group
9.1.2.3. By Treatment Line
9.1.2.4. By DISTRIBUTION
CHANNEL
9.1.2.5. By Country
9.1.2.5.1. The U.S.
9.1.2.5.2. Canada
9.1.2.5.3. Mexico
10. Europe Blinatumomab
Market: Estimates & Forecast Trend
Analysis
10.1. Europe Blinatumomab Market
Assessments & Key Findings
10.1.1. Europe Blinatumomab Market
Introduction
10.1.2. Europe Blinatumomab Market Size
Estimates and Forecast (US$ Million) (2019 – 2034)
10.1.2.1. By INDICATION
10.1.2.2. By Age Group
10.1.2.3. By Treatment Line
10.1.2.4. By DISTRIBUTION
CHANNEL
10.1.2.5. By Country
10.1.2.5.1. Germany
10.1.2.5.2. U.K.
10.1.2.5.3. France
10.1.2.5.4. Italy
10.1.2.5.5. Spain
10.1.2.5.6. Russia
10.1.2.5.7. Rest of Europe
11. Asia Pacific Blinatumomab
Market: Estimates & Forecast Trend
Analysis
11.1. Asia Pacific Market Assessments
& Key Findings
11.1.1. Asia Pacific Blinatumomab Market
Introduction
11.1.2. Asia Pacific Blinatumomab Market
Size Estimates and Forecast (US$ Million) (2019 – 2034)
11.1.2.1. By INDICATION
11.1.2.2. By Age Group
11.1.2.3. By Treatment Line
11.1.2.4. By DISTRIBUTION
CHANNEL
11.1.2.5. By Country
11.1.2.5.1. China
11.1.2.5.2. Japan
11.1.2.5.3. India
11.1.2.5.4. Australia
11.1.2.5.5. South Korea
11.1.2.5.6. ASEAN
11.1.2.5.7. Rest of Asia Pacific
12. Middle East & Africa Blinatumomab
Market: Estimates & Forecast Trend
Analysis
12.1. Middle East & Africa Market
Assessments & Key Findings
12.1.1. Middle
East & Africa Blinatumomab
Market Introduction
12.1.2. Middle
East & Africa Blinatumomab
Market Size Estimates and Forecast (US$ Million) (2019 – 2034)
12.1.2.1. By INDICATION
12.1.2.2. By Age Group
12.1.2.3. By Treatment Line
12.1.2.4. By DISTRIBUTION
CHANNEL
12.1.2.5. By Country
12.1.2.5.1. U.A.E.
12.1.2.5.2. Saudi Arabia
12.1.2.5.3. Egypt
12.1.2.5.4. South Africa
12.1.2.5.5. Rest of Middle East & Africa
13. South America
Blinatumomab Market: Estimates &
Forecast Trend Analysis
13.1. South America Market Assessments
& Key Findings
13.1.1. South America Blinatumomab
Market Introduction
13.1.2. South America Blinatumomab
Market Size Estimates and Forecast (US$ Million) (2019 – 2034)
13.1.2.1. By INDICATION
13.1.2.2. By Age Group
13.1.2.3. By Treatment Line
13.1.2.4. By DISTRIBUTION
CHANNEL
13.1.2.5. By Country
13.1.2.5.1. Brazil
13.1.2.5.2. Argentina
13.1.2.5.3. Colombia
13.1.2.5.4. Rest of South America
14. Competition Landscape
14.1. Global Blinatumomab Market
Competition Matrix & Benchmarking, by Leading Players / Innovators /
Emerging Players / New Entrants
14.2. Global Blinatumomab Market
Competition White Space Analysis, By Treatment Line
14.3. Global Blinatumomab Market
Competition Heat Map Analysis, By Treatment Line
14.4. Global Blinatumomab Market
Concentration & Company Market Shares (%) Analysis, 2022
15. Company Profiles
15.1.
Amgen
15.1.1. Company Overview & Key Stats
15.1.2. Financial Performance & KPIs
15.1.3. Product Portfolio
15.1.4. Business Strategy & Recent
Developments
* Similar details would be provided
for all the players mentioned below
15.2. Others
16. Research
Methodology
16.1. External Transportations /
Databases
16.2. Internal Proprietary Database
16.3. Primary Research
16.4. Secondary Research
16.5. Assumptions
16.6. Limitations
16.7. Report FAQs
17. Research Findings & Conclusion
Quality Assurance Process
- We Market Research’s Quality Assurance program strives to deliver superior value to our clients.
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
- Project kickoff meeting with client
- Conduct frequent client communications
- Form project steering committee
- Assign a senior SR executive as QA Executive
- Conduct internal editorial & quality reviews of project deliverables
- Certify project staff in SR methodologies & standards
- Monitor client satisfaction
- Monitor realized value post-project
Case Study- Automotive Sector
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
Solution
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
Market Estimates and Forecast
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Case Study- ICT Sector
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.
Frequently Asked Questions
What is the market size of Blinatumomab Market in 2024?
Blinatumomab Market was valued at USD xx Million in 2024.
What is the growth rate for the Blinatumomab Market?
Blinatumomab Market size will increase at approximate CAGR of xx% during the forecasted period.
Which are the top companies operating within the market?
Major companies operating within the Blinatumomab Market are Amgen and Other.
Which region dominates the Blinatumomab Market?
North America dominates the market with an active share of 47%.
}})
Select a license type that suits your business needs
US $3499
Only Three Thousand Four Hundred Ninety Nine US dollar
- 1 User access
- 15% Additional Free Customization
- Free Unlimited post-sale support
- 100% Service Guarantee until achievement of ROI
US $4499
Only Four Thousand Four Hundred Ninety Nine US dollar
- 5 Users access
- 25% Additional Free Customization
- Access Report summaries for Free
- Guaranteed service
- Dedicated Account Manager
- Discount of 20% on next purchase
- Get personalized market brief from Lead Author
- Printing of Report permitted
- Discount of 20% on next purchase
- 100% Service Guarantee until achievement of ROI
US $5499
Only Five Thousand Four Hundred Ninety Nine US dollar
- Unlimited User Access
- 30% Additional Free Customization
- Exclusive Previews to latest or upcoming reports
- Discount of 30% on next purchase
- 100% Service Guarantee until achievement of ROI